Society for Immunotherapy of Cancer (SITC) 27th Annual Meeting

SITC is ideally positioned to meet the identified needs of our attendees. SITC’s strength lies in its history of organizing successful scientific conferences that gather clinicians and scientists from around the globe to interact and discuss the most important issues in cancer immunotherapy. By addressing these needs, SITC advances effective, efficient research and interaction on promising cancer therapies with biological and immunological agents. Through its integrated programs, SITC promotes productive collaboration among scientists and with other organizations in the field. Ultimately this scientific exchange and collaborative environment will lead to better cancer patient outcomes with novel cancer immunotherapies.

The SITC 27th Annual Meeting program format and content is designed to address identified needs/practice gaps and promotes:

- Exchange between basic and clinical researchers, thus improving the caliber of the science and promoting translation
- Discussion on potential hurdles in cancer immunotherapy from the trial design and regulatory perspective
- Integrated understanding of the state of cancer immunotherapy research in today’s environment, identification of potential funding opportunities, and mentoring of junior investigators
- Discussion of novel therapies and applications based on the research presented
- Interactions with industry to promote access to novel agents for clinical development

The SITC 27th Annual Meeting offers a unique forum for special updates, major national and international initiatives, and important society projects including:

- National Cancer Institute (NCI) Update
- US Food and Drug Administration (FDA) Update
- Cancer Immunotherapy Trials Network (CITN) Update
- World Immunotherapy Council (WIC) Update

PURPOSE

The SITC 27th Annual Meeting provides a multidisciplinary educational environment composed of cutting-edge research, informative oral presentations, poster presentations, and valuable networking opportunities unique to SITC.
Intended Audience

The audience for the 27th Annual Meeting is basic and clinical investigators from academic institutions, industry and regulatory agencies, including clinicians, basic and translational researchers, graduate students, postdoctoral fellows, and allied health professionals involved in cancer research.

PROGRAM GOALS

- Exchange information on the most recent advances in tumor immunology and cancer immunotherapy
- Convey recent advances in biology and immunotherapy as they relate to specific cancers and various immunotherapy modalities, cell subsets, animal models, and aspects of negative regulation in the tumor microenvironment
- Identify promising research opportunities, new techniques, and clinical applications incorporating these advances
- Establish dialogue between academia, industry, and government on these advances

EXPECTED LEARNER OUTCOMES

Upon completion of this program, the participants will be able to:

- Summarize the most recent advances in tumor immunology and cancer immunotherapy
- Integrate recent advances in cancer immunology and immunotherapy into basic, clinical, and translational research
- Incorporate new research and techniques into clinical applications for cancer immunotherapy
- Establish and solidify collaborations among the various members of academia, industry, government and clinical practices to promote clinical evaluation of these advances in more efficient trials



+ show speakers and program
Alessandra Cesano, MD, PhD
Nodality

Ronald DeMatteo, MD, FACS
Memorial Sloan-Kettering Cancer Center

Bernard A. Fox, PhD
Earle A. Chiles Research Institute

Phillip D. Greenberg, MD
University of Washington

Pawel Kalinski, MD, PhD
University of Pittsburgh Cancer Institute

Michael H. Kershaw, PhD
Peter MacCallum Cancer Centre

Edmund C. Lattime, PhD
The Cancer Institute of New Jersey

Cornelis J.M. Melief, MD, PhD
Leiden University Medical Center

William Merritt, PhD
National Cancer Institute

David H. Munn, MD
Georgia Health Sciences University

Gary P. Nolan, PhD
Stanford School of Medicine

Pamela S. Ohashi, PhD
Ontario Cancer Institute

Raj K. Puri, MD, PhD
US Food and Drug Administration, CBER

Laszlo G. Radvanyi, PhD
MD Anderson Cancer Center

Nicholas P. Restifo, MD
National Cancer Institute

Antoni Ribas, MD
UCLA Medical Center

Steven A. Rosenberg, MD, PhD
National Cancer Institute

Jon Rowley, MD, PhD
Lonza Walkersville, Inc.

Michel Sadelain, MD, PhD
Memorial Sloan-Kettering Cancer Center

Robert D. Schreiber, PhD
Washington University School of Medicine

David F. Stroncek, MD
National Institutes of Health

Richard Vile, PhD
Mayo Clinic

Theresa L. Whiteside, PhD
University of Pittsburgh Cancer Institute

Cassian Yee, MD
Fred Hutchinson Cancer Research Center

Laurence Zitvogel, MD, PhD
Institute Gustave Roussy

26 Oct - 28 Oct 2012

North Bethesda, MD
United States of America
meeting website